News | April 16, 2013

Stenting dramatically improves treatment access for dialysis patients

Abstract of the year: RENOVA trial results show stent grafts keep access sites open significantly longer than angioplasty alone

April 16, 2013 — Kidney failure patients on dialysis derive long-term benefit from the minimally invasive placement of a stent that improves the function of dialysis access grafts, according to 12-month clinical trial results being presented at the Society of Interventional Radiology's 38th Annual Scientific Meeting in New Orleans.

"Results of the study exceeded our expectations, and that is a boon for dialysis patients," said Ziv J Haskal, M.D., FSIR, lead author and professor of vascular and interventional radiology at the University of Maryland School of Medicine in Baltimore. "Dialysis is very demanding, and anything that prevents access sites from failing and reduces the need for invasive treatments of surgery will dramatically improve patients' quality of life — while reducing health care costs," he added.

Every year nearly 400,000 people undergo dialysis, said Haskal. Doctors access and filter the blood through delicate grafts or veins that often collapse because they cannot handle the high-pressure circuit of purified blood being fed back into the body, forcing doctors to continually reopen them or create new treatment access sites. Twelve-month results of RENOVA, a prospective, multicenter, randomized trial, show these dialysis sites can be successfully kept open using tiny scaffolds called stent grafts for far longer than previously reported. In the study — named SIR's Abstract of the Year — 270 dialysis patients treated for collapsed access sites at 28 U.S. centers were randomized and 138 subjects underwent stent grafts while the remaining 132 had balloon angioplasty. After 12-month follow-up, researchers found that two and half times more patients in the stent graft group were able to continue to use their dialysis access grafts, than those who were being treated by balloon angioplasty alone (without invasive interim procedures). Until this data, grafts have been considered short-term solutions, with 75 percent requiring invasive interventions in under a year, said Haskal.

An estimated one in 10 Americans has some form of chronic kidney disease, according to the National Institutes of Health. End-stage renal disease means the kidneys have failed and can no longer filter waste products from the blood. This condition is fatal without a kidney transplant or dialysis to prevent blood poisoning. An arteriovenous fistula is the gold standard for dialysis access and involves creating a natural blood vessel bypass, but many patients, especially those who are too ill to undergo the invasive surgery, have an arteriovenous graft — a plastic tube sewn into the vein, which easily clogs, explained Haskal.

"This area where the graft is sewn in, that allows blood to flow back up the arm toward the heart, has particular turbulence," said Haskal. "That turbulence, like a river bend, tends to incite tissue growth at the sides. Just like a river depositing sediment along a bend, these veins thicken and narrow. More than 100,000 angioplasties are performed a year due to this narrowing. What this stent method does is not only reopen the vein, but turn the graft into an inline flow, so that the blood enters the vein at a more natural angle," he added.

 The stents, made of a medical-grade plastic, are implanted at the time of balloon angioplasty, a minimally invasive technique interventional radiologists perform using just a small incision and medical imaging to guide it to the narrowed vein. A small balloon is inflated expanding the vein and setting the stent in place. The resulting reduction of wear and tear due to these stent grafts helps dialysis access sites stay healthy and open months and even years longer than researchers had hoped.

"It was a wholly foreign concept when we started," said Haskal. "People told me it was crazy. Anecdotally we now have patients who have these stent grafts that are still open after three years. That is practically unheard of," said Haskal, who is also editor of the Journal of Vascular and Interventional Radiology. "This controlled study proves that we can achieve durable long-term solutions for these patients, reducing their invasive procedures and thus improving their quality of life," he added.

For more information: www.sirweb.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init